Showing results (371-380 of 682) with videos related to

Sort By:
Pageof 69
Gynecologic Oncology|September 7, 2010
MTHFR polymorphisms in relation to ovarian cancer riskKathryn L Terry, Shelley S Tworoger, Ellen L Goode, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2015
Structural basis for mutation-induced destabilization of profilin 1 in ALSSivakumar Boopathy, Tania V Silvas, Maeve Tischbein, et al.
Cancer Cell|July 21, 2015
The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic PotentialStephen H K Wong, David L Goode, Masayuki Iwasaki, et al.
Toxicology and Applied Pharmacology|February 1, 1990
Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male ratB L Neubauer, R L Goode, K L Best, et al.
International Journal of Cancer|May 13, 2003
Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onsetErin M Conlon, Ellen L Goode, Mark Gibbs, et al.
Gynecologic Oncology|October 2, 2017
Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancerDiogo Torres, Amanika Kumar, Sumer K Wallace, et al.
BMC Cancer|September 8, 2009
No association between a candidate TCF7L2 variant and risk of breast or ovarian cancerEllen L Goode, Csilla Szabo, Ludmila Prokunina-Olsson, et al.
The Prostate|January 1, 1993
LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male ratsB L Neubauer, K L Best, T R Blohm, et al.
American Journal of Human Genetics|March 26, 1999
Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancerM Gibbs, L Chakrabarti, J L Stanford, et al.
BMC Proceedings|December 19, 2009
Assessment of genotype imputation methodsJoanna M Biernacka, Rui Tang, Jia Li, et al.
Pageof 69